Optimizing CDK4/6 Inhibitor Use: Dosing, Safety, and Pharmacist Management

In this episode, Optimizing CDK4/6 Inhibitor Use: Dosing, Safety, and Pharmacist Management, the experts explore the following questions:

What are the differences in dosing schedules between the 3 FDA-approved CDK4/6 inhibitors?

How do the adverse event profiles of the 3 approved CDK4/6 inhibitors differ from each other?

What is the role of the pharmacist for monitoring for and managing the adverse events associated with CDK4/6 inhibitors?

The breast cancer panel examined Tte three FDA-approved CDK4/6 inhibitors—palbociclib, ribociclib, and abemaciclib—each having distinct dosing schedules, with Palbociclib and ribociclib typically given on a 3-weeks-on, 1-week-off cycle, while abemaciclib is administered continuously twice daily. These differences can impact patient adherence, as more frequent or continuous dosing may present challenges in maintaining consistent therapy. Adverse event profiles also vary: palbociclib and ribociclib are more commonly associated with neutropenia, whereas abemaciclib shows higher rates of diarrhea and fatigue. Pharmacists play a key role in monitoring for these toxicities, providing patient education, and recommending supportive care or dose adjustments when needed. Electronic health records (EHR) can be leveraged to track lab values, flag adverse events, and facilitate communication with providers for timely interventions. By integrating dosing considerations, safety monitoring, and adherence support, pharmacists help optimize the safe and effective use of CDK4/6 inhibitors in clinical practice.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, CDK4/6 Inhibitor Dose Adjustments: Clinical Scenarios and Impact on Outcomes, features the panelists advancing their conversation and focusing on the clinical situations in which dose modifications of CDK4/6 inhibitors are warranted, including adverse events such as neutropenia, diarrhea, or hepatotoxicity. Faculty also discuss evidence on how dose adjustments affect treatment efficacy and patient outcomes, emphasizing strategies to maintain both safety and therapeutic benefit.